Clinical Trial Update: Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ABI-007 (nab-paclitaxel) combined with carboplatin and gemcitabine as first-line therapy for advanced urothelial cancer; the study was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• ABI-007 (nab-paclitaxel) (nab-paclitaxel)
• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Urothelial Cancer, Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-09-19